cue, a revolutionary device for tracking health information at the molecular level. for the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin d, fertility, influenza, and testosterone in just minutes, at home. cue sends the data via bluetooth 4.0 to the user's smartphone, where the free cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level. by simply adding a noninvasive droplet of saliva, blood, or nasal swab, you can access deep information about your body only previously available from a lab -- on demand and on your schedule. interactive charts put you in touch with your health, making it easy to discover new trends, monitor your progress, and share it with the people who matter most. cue also features life feed, an incredible new smartphone-based way to visualize the daily effect of activity, food, and sleep on your molecular health. cue makes research-based recommendations for foods proven to sup
Company profile
Ticker
HLTH
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cue Inc.
SEC CIK
Corporate docs
Subsidiaries
CHP HC, LLC • TrustedMedRx, LLC • Cue Health India Private Limited • Cue Health Sağlik Yazilimi Hizmetleri Limited ...
HLTH stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
16 May 24
NT 10-Q
Notice of late quarterly filing
16 May 24
8-K
Cost Associated with Exit or Disposal Activities
1 May 24
8-K
Departure of Directors or Certain Officers
24 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
PRE 14A
Preliminary proxy
11 Apr 24
8-A12B/A
Registration of securities on exchange (amended)
9 Apr 24
8-K
Entry into a Material Definitive Agreement
9 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
Transcripts
HLTH
Earnings call transcript
2023 Q4
13 Mar 24
HLTH
Earnings call transcript
2023 Q3
8 Nov 23
HLTH
Earnings call transcript
2023 Q2
9 Aug 23
HLTH
Earnings call transcript
2023 Q1
10 May 23
HLTH
Earnings call transcript
2022 Q4
15 Mar 23
HLTH
Earnings call transcript
2022 Q3
13 Nov 22
HLTH
Earnings call transcript
2022 Q2
11 Aug 22
HLTH
Earnings call transcript
2021 Q1
12 May 22
HLTH
Earnings call transcript
2021 Q4
30 Mar 22
HLTH
Earnings call transcript
2021 Q3
13 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 112.25 mm | 112.25 mm | 112.25 mm | 112.25 mm | 112.25 mm | 112.25 mm |
Cash burn (monthly) | 5.70 mm | 16.14 mm | 21.57 mm | 23.71 mm | 4.18 mm | 13.40 mm |
Cash used (since last report) | 43.45 mm | 123.10 mm | 164.45 mm | 180.81 mm | 31.88 mm | 102.16 mm |
Cash remaining | 68.80 mm | -10.84 mm | -52.20 mm | -68.56 mm | 80.38 mm | 10.09 mm |
Runway (months of cash) | 12.1 | -0.7 | -2.4 | -2.9 | 19.2 | 0.8 |
Institutional ownership, Q4 2023
30.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 7 |
Closed positions | 34 |
Increased positions | 7 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 7.12 bn |
Total shares | 48.36 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tarsadia Capital | 10.68 mm | $1.74 bn |
Oakmont | 9.60 mm | $1.56 bn |
Decheng Capital | 8.98 mm | $1.46 bn |
Jabodon PT | 3.98 mm | $647.00 k |
GS Goldman Sachs | 3.93 mm | $638.12 mm |
Vanguard | 3.88 mm | $631.20 mm |
Temasek | 3.13 mm | $507.81 mm |
Bleichroeder | 1.00 mm | $162.50 mm |
Verition Fund Management | 861.40 k | $139.98 mm |
Renaissance Technologies | 466.60 k | $76.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Mar 24 | Clint Sever | Common Stock | Payment of exercise | Dispose F | No | No | 0.19 | 20,456 | 3.89 k | 4,379,914 |
5 Mar 24 | Pollard Randall E. | Common Stock | Payment of exercise | Dispose F | No | No | 0.25 | 7,304 | 1.83 k | 503,202 |
5 Mar 24 | Christopher K Achar | Common Stock | Payment of exercise | Dispose F | No | No | 0.25 | 8,482 | 2.12 k | 1,616,722 |
5 Mar 24 | Aasim Javed | Common Stock | Payment of exercise | Dispose F | No | No | 0.25 | 13,327 | 3.33 k | 1,010,149 |
5 Mar 24 | Clint Sever | Common Stock | Payment of exercise | Dispose F | No | No | 0.25 | 12,604 | 3.15 k | 4,400,370 |
News
Reported Earlier, FDA Issues Warning To Cue Health Over Emergency Use Authorized (EUA) COVID-19 Test
14 May 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Cue Health Reveals Strategic Actions; Names Clint Sever As CEO; Seeks To Refine And Strengthen Its Overarching Strategy And Cost Structure
20 Mar 24
Press releases
Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)
13 May 24
Cue Health Announces Strategic Actions to Position Company for Next Stage
20 Mar 24
Cue Health Reports Fourth Quarter 2023 Financial Results
13 Mar 24
Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24